Lates News
RAPT Therapeutics (RAPT.US): The Q3 2025 financial report achieved revenue of $0, a decrease from the previous value of $0. Earnings per share were -$0.65, an improvement from the previous value of -$3.79 and better than the expected value of -$0.86.
Latest

